Privi FY26: Higher margins, lower leverage, and a busy expansion calendar

Privi Speciality Chemicals ended FY26 with a sharp improvement in profitability and a clearer roadmap for the next capacity cycle. Consolidated total income rose to INR 2,582.92 crore in FY26, up 21.7% year on year. EBITDA increased 40.3% to INR 665.45 crore, taking the EBITDA margin to 25.8% from 22.3% in FY25. PAT attributable to the company climbed to INR 327.54 crore, up 75.2%, and PAT margin expanded to 12.7%.

The March quarter maintained the same direction, even with the normal quarter-to-quarter noise that comes with annual raw material contracts. Q4 FY26 total income was INR 725.70 crore, up 15.5% year on year. EBITDA grew 25.1% to INR 184.41 crore with a 25.4% margin, while PAT attributable to the company rose 40.9% to INR 93.70 crore.

Privi positions itself as India’s leading manufacturer of aroma chemicals, with a 30+ year operating history and a portfolio spanning 75+ products. The company also emphasizes its scale and operating footprint, stating 48,000 MTPA of production capacity, seven manufacturing facilities, two R&D centres, and exports to 40+ countries. The management narrative through the presentation and the May 12, 2026 earnings call was consistent: growth is being driven by volume, improved mix in value-added products, and operating efficiency. The company also highlighted strong operating cash flow and a reduction in leverage, even while continuing a high capex cycle.

FY26 in numbers: growth plus margin expansion

FY26 reflected a mix of growth and cost discipline. In the concall, the CFO quantified volume growth at about 6.5% year on year and indicated that the balance of revenue growth came from product mix and pricing, including roughly an 8% increase in prices. Input costs were described as relatively stable during the year, and management pointed to operational initiatives and tighter control on manufacturing and administrative expenses as margin supports.

A key balance sheet improvement was visible in leverage ratios. Net debt to equity was presented at 0.62x in FY26, down from 0.95x in FY25. Net debt to EBITDA improved to 1.33x from 2.25x. Management also highlighted that the working capital cycle reduced to 117 days in FY26.

Cash flows and capital allocation: funding growth while reducing debt

The presentation described FY26 operating cash flow of INR 550.09 crore versus INR 281.11 crore in FY25. Investing cash flow was negative at INR 358.08 crore, consistent with continued capex. Financing cash flow was negative at INR 197.67 crore, reflecting a year of debt reduction.

Management highlighted that after investing about INR 320 crore in capex, total debt reduced by INR 113 crore during the year. This is consistent with the broader theme of disciplined capital allocation: continue capacity additions and new product projects, while improving leverage and maintaining liquidity. The CFO also stated the board recommended a dividend of INR 10 per share for FY26.

In Q4, a key investor concern was a sequential gross margin dip. Management explained that a portion of export revenues is contract-driven and that annual raw material contracts can overlap into Q4, which is the first quarter of the calendar year, causing temporary distortions. The management message was to evaluate performance on an annualized basis.

Capacity expansion and new products: the next 12 to 24 months

A major operational milestone is Phase 1 of the capex expansion program, which management said is on track to complete by June 30, 2026. After this phase, total installed capacity is expected to increase to 54,000 MTPA. The company described a calibrated ramp-up phase, with the incremental capacities commissioned progressively across coming quarters based on demand visibility.

In parallel, management said Phase 2 of a multi-speciality aroma chemicals project is progressing as planned. While the transcript did not provide a rupee figure for Phase 2, the company positioned it as an investment intended to support the next leg of revenue and profitability growth.

New molecules are also central to the medium-term plan. On the earnings call, management confirmed Maltol, Ethyl Maltol, and Cyclopentanone projects are in full swing. They guided to mechanical completion by the end of the first quarter of the next financial year, followed by trials and then commercial production typically within about a month. They also indicated customer lab samples are already approved, implying parallel qualification is underway.

The longer-cycle project is furfural and backward integration. Management stated it intends to first establish finished goods and then proceed to backward integration, with a timeline of about two years, pointing to FY28 to FY29.

PRIGIV: the JV turning profitable and scaling up

PRIGIV, the strategic JV with Givaudan (Privi 51%, Givaudan 49%), is highlighted as a growing contributor. The presentation stated PRIGIV manufactures 40+ specialty products exclusively for Givaudan. It also stated that PRIGIV achieved positive PAT in Q4 FY26.

Two capital supports were highlighted. First, an additional INR 50 crore equity infusion by Privi and Givaudan to support capex for growth opportunities. Second, a roughly INR 180 crore non-interest-bearing trade advance from Givaudan, positioned as a balance-sheet support to reduce debt and interest costs.

On the call, management indicated PRIGIV sales are expected to rise to about INR 130 crore in the current financial year, up from about INR 55 crore last year. Management also spoke of an ambition to reach about INR 300 crore of revenue in 3 to 4 years, with decent margins.

Corporate simplification and the green chemistry agenda

Privi also discussed a proposed amalgamation involving Priiv Fine Sciences Private Limited and Privi Biotechnologies Private Limited into the listed company. The stated rationale includes broadening the portfolio via products like PriVial, Anethole, and Cyclamen Aldehyde, strengthening R&D, and integrating biotech capabilities.

On process timeline, the CFO said the company has received observation letters with no objection from both stock exchanges and will proceed with NCLT filings. They expect the final NCLT approval during FY27.

On sustainability, Privi highlighted that it has progressed from EcoVadis Bronze in 2020 to Platinum Top 1% in May 2025. It also presented quantified targets, including reductions in Scope 1 and 2 emissions by 2032 (vs base year 2022), a Scope 3 reduction target by 2034 (vs base year 2024), renewable energy sourcing targets, and water recycling targets.

What to watch from here

Privi’s FY26 narrative was built around three pillars: stronger profitability, lower leverage, and a structured pipeline of capacity and specialty additions. The near-term marker is execution of the June 2026 Phase 1 completion and subsequent ramp-up. Another marker is whether PRIGIV continues to scale profitably after its first profitable quarter.

Management also reiterated its longer-term 5k:1k vision, targeting INR 5,000 crore revenue and INR 1,000 crore plus EBITDA by FY29 to FY30. The presentation also stated that EBITDA margins are expected to sustain north of 20%, supported by operational efficiency and product mix. As always, the execution of new molecules, capex ramp-up, and working capital discipline will determine how efficiently that growth translates into returns.